肠道微生物群与骨髓增生异常综合征：当前的知识现状及未来展望
Intestinal microbiome and myelodysplastic syndromes: Current state of knowledge and perspectives for future.
作者信息
Simunic Marin, McGraw Kathy, Pavletic Steven Z, Rashidi Armin
机构信息
Immune Deficiency Cellular Therapy Program (ID-CTP), National Cancer Institute, National Institutes of Health, Bethesda, MD, USA; Myeloid Malignancies Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA; Department of Hematology, Clinic for Internal Medicine, Clinical Hospital Center, Split, Croatia.
Immune Deficiency Cellular Therapy Program (ID-CTP), National Cancer Institute, National Institutes of Health, Bethesda, MD, USA; Myeloid Malignancies Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
出版信息
Semin Hematol. 2024 Dec;61(6):442-448. doi: 10.1053/j.seminhematol.2024.10.006. Epub 2024 Oct 28.
The intestinal microbiome has been mechanistically linked with health and many disease processes. Cancer is no exception. Both in solid tumors and hematologic malignancies, there is increasing evidence supporting the involvement of the intestinal microbiome in tumor development, disease progression, response to treatment, and treatment toxicity. Consistent with microbiome mediation of the immune system and the potent effect of the immune system on cancer, the most compelling evidence has been obtained in the setting of cancer immunotherapy. Here, we review the current state of knowledge about microbiome effects in myelodysplastic syndromes, identify gaps and challenges in related research, and provide insights for future work.
肠道微生物群在机制上与健康和许多疾病过程相关联。癌症也不例外。在实体瘤和血液系统恶性肿瘤中，越来越多的证据支持肠道微生物群参与肿瘤发生、疾病进展、对治疗的反应以及治疗毒性。与微生物群对免疫系统的调节作用以及免疫系统对癌症的强大影响相一致，最有说服力的证据来自癌症免疫治疗领域。在此，我们综述了关于微生物群在骨髓增生异常综合征中作用的现有知识状态，识别相关研究中的差距和挑战，并为未来的工作提供见解。
Zotero 插件